Vaccination remains a vital strategy in the prevention of infectious disease.
Commercial vaccine formulations contain a range of additives or manufacturing residuals, which may contribute to patient concerns about vaccine safety.
Primary health care professionals are well placed to address patient concerns about vaccine safety. We describe the key constituents present in vaccines, discuss issues related to safety and acceptability of these constituents, and provide a table highlighting constituents of commercially available vaccines in Australia.
- 1. World Health Organization. Vaccines, immunization and biologicals: diseases and vaccines. The history of vaccination. Available at: http://www.who.int/vaccines-diseases/history/history.shtml (accessed Dec 2005).
- 2. Australian Bureau of Statistics. Occasional paper: vaccination coverage in Australian children — ABS statistics and the Australian Childhood Immunisation Register (ACIR). Canberra: ABS, 2003. (ABS Catalogue No. 4813.0.55.001.)
- 3. Gilbert GL, Gidding HF, Backhouse J, McIntyre PB. Varicella seroprevalence and vaccine uptake in preschool children [letter]. Med J Aust 2005; 182: 42. <MJA full text>
- 4. Begg N, Ramsay M, White J, Bozoky Z. Media dents confidence in MMR vaccine. BMJ 1998; 316: 561.
- 5. Offit PA, Jew RK. Addressing parents’ concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 2003; 112: 1394-1397.
- 6. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360: 1737-1741.
- 7. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: NHMRC, 2003. Available at: http://immunise.health.gov.au/handbook.htm (accessed Dec 2005).
- 8. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-641.
- 9. Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004; 363: 750.
- 10. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004; 114: 793-804.
- 11. Patrizi A, Rizzoli L, Vincenzi C, et al. Sensitization to thimerosal in atopic children. Contact Dermatitis 1999; 40: 94-97.
- 12. Vogt T, Landthaler M, Stolz W. Generalized eczema in an 18-month-old boy due to phenoxyethanol in DPT vaccine. Contact Dermatitis 1998; 38: 50-51.
- 13. Georgitis JW, Fasano MB. Allergenic components of vaccines and avoidance of vaccination-related adverse events. Curr Allergy Rep 2001; 1: 11-17.
- 14. Finn TM, Egan W. Vaccine additives and manufacturing residuals in the United States — licensed vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders, 2004.
- 15. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002; 20 Suppl 3: S34-S39.
- 16. Agency for Toxic Substances and Disease Registry. Toxicological profile for aluminium. Atlanta: US Department of Health and Human Services, Public Health Service, 1999. Available at: http://www.atsdr.cdc.gov/toxprofiles/tp22.html (accessed Dec 2005).
- 17. Kaaber K, Nielsen AO, Veien NK. Vaccination granulomas and aluminium allergy: course and prognostic factors. Contact Dermatitis 1992; 26: 304-306.
- 18. Fawcett HA, Smith NP. Injection-site granuloma due to aluminum. Arch Dermatol 1984; 120: 1318-1322.
- 19. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004; 4: 84-90.
- 20. Brenner A. Macrophagic myofasciitis: a summary of Dr. Gherardi’s presentations. Vaccine 2002; 20 Suppl 3: S5-S6.
- 21. Rottem M, Shoenfeld Y. Vaccination and allergy. Curr Opin Otolaryngol Head Neck Surg 2004; 12: 223-231.
- 22. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998; 133: 624-628.
- 23. Andrews RM, Kempe AE, Sinn KK, Herceg A. Vaccinating children with a history of serious reactions after vaccination or of egg allergy. Med J Aust 1998; 168: 491-494. <MJA full text>
- 24. Castle P, Robertson JS. Summary and conclusion. In: Brown F, Cartwright T, Horaud F, Spieser JM, editors. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals: viral safety and regulatory aspects. Basel: Karger, 1999.
- 25. Grabenstein JD. Where medicine and religion intersect. Ann Pharmacother 2003; 37: 1338-1339.
- 26. Rudd G. Is vaccination complicit with abortion? Ann Pharmacother 2003; 37: 1340-1341.
- 27. Maher DP. Vaccines, abortion and moral coherence. Natl Cathol Bioeth Q 2002; 2: 51-67.
- 28. Bashir A, Asif M, Lacey FM, et al. Concordance in Muslim patients in primary care. Int J Pharmacy Pract 2001; 9(Suppl): R78.
- 29. Islamic Organization for Medical Sciences. The use of unlawful or juridically unclean substances in food and medicine. Question 104. Islam SET [website]. Available at: http://www.islamset.com/qa/index.html (accessed Dec 2005).
- 30. Mynors G, Ghalamkari H, Beaumont S, et al. Informed choice in medicine taking. Drugs derived from pigs and their clinical alternatives: an introductory guide. London: Medicines Partnership, 2004. Available at: http://www.medicines-partnership.org/our-publications/drugs-of-porcine-origin (accessed Dec 2005).
- 31. Minor PD, Will RG, Salisbury D. Vaccines and variant CJD. Vaccine 2000; 19: 409-410.
- 32. European Agency for the Evaluation of Medicinal Products. Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines. London: European Medicines Agency, 2001. Available at: http://www.emea.eu.int/pdfs/human/bwp/081901en.pdf (accessed Dec 2005).
- 33. US Food and Drug Administration. Center for Biologics Evaluation and Research. Questions and answers on bovine derived materials used in vaccine manufacturing. Available at: http://www.fda.gov/cber/bse/bseqa.htm#a3 (accessed Mar 2005).
- 34. Therapeutic Goods Administration. Questions and answers on BSE risk associated with the use of materials of bovine origin during the manufacture of vaccines. Available at: http://www.tga.gov.au/docs/html/bsefaq.htm (accessed Mar 2005).
- 35. Egbert GB, Mascolo ED, Egan W. Vaccine manufacturing. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: WB Saunders; 2004.
- 36. Burgess MA, McIntyre PB. Vaccine-associated paralytic poliomyelitis. Commun Dis Intell 1999; 23: 80-81.
- 37. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997; 24: 1139-1146.
- 38. Hauptmann M, Lubin JH, Stewart PA, et al. Mortality from solid cancers among workers in formaldehyde industries. Am J Epidemiol 2004; 159: 1117-1130.
- 39. Russell M, Pool V, Kelso JM, Tomazic-Jezic VJ. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004; 23: 664-667.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.